Nilotinib is another second-generation TKI that has been evaluated in a small open-label study enrolling 10 SSc patients, demonstrating not only potential clinical efficacy on cutaneous involvement (although the study was not adequately controlled) but also the ability to induce a significant downregulation of the expression of genes involved in the PDGFR and TGFBR pathways [74]. The gene discussed is PDGFRB; the disease is systemic sclerosis.